This trial will test if a new drug is effective, safe, and tolerable for treating cancer-related cachexia and elevated GDF 15 levels.
1 Primary · 7 Secondary · Reporting Duration: Week 12
Experimental Treatment
Non-Treatment Group
168 Total Participants · 4 Treatment Groups
Primary Treatment: ponsegromab · Has Placebo Group · Phase 2
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:California | 100.0% |
18 - 65 | 100.0% |
Carta - Clinical Associates in Research Therapeutics of America, LLC | 100.0% |
Met criteria | 100.0% |